Early Treatment Failure in Patients With Relapsed/Refractory Multiple Myeloma Receiving Bispecific T-Cell Engagers: Development and Validation of the CHARGE Prognostic Index
Journal of Clinical Oncology · 13.11.2026
DOI: 10.1200/jco-26-01039 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Oncology, online erschienen am 13.11.2026. Verfasst von Saurabh Zanwar und 50 weiteren Autor:innen. Beteiligte Einrichtung: Mayo Clinic, Rochester, MN. Die Arbeit nennt 36 Literaturangaben.
Abstract (Originalsprache)
Purpose
Outcomes with bispecific T-cell engagers (TCEs) in relapsed/refractory multiple myeloma (RRMM) are heterogeneous. A practical tool to guide prognosis is needed. We developed a model integrating clinical, biological, and treatment-related variables to predict progression-free survival (PFS) in patients receiving B-cell maturation antigen (BCMA)- or G-protein–coupled receptor class 5 member D-directed TCEs.
Methods
We evaluated outcomes of 577 BCMA-directed and 366 talquetamab treatments across 15 US Multiple Myeloma Immunotherapy Consortium centers. Variables significantly associated with inferior PFS in a multivariate Cox model were incorporated into a prognostic score and validated in an independent multicenter International Myeloma Foundation cohort.
Results
With a median follow-up of 8.4 months, the median PFS was 6.4 months (7.0 months for BCMA TCE; 6.1 months for talquetamab); 92% of patients were triple-class-refractory. Six variables significantly associated with inferior PFS—high-risk cytogenetic abnormalities (HRCAs) [del(17p) or ≥2 HRCAs], hyperferritinemia (≥600 ng/mL), anemia (hemoglobin
Autor:innen und Institutionen
- Mayo Clinic, Rochester, MN.
- H. Lee Moftt Cancer Center, Tampa, FL.
- MD Anderson Cancer Center, Houston, TX.
- Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
- Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, FL.
- Cleveland Clinic, Cleveland, OH.
ORCID-Profile: Saurabh Zanwar, Doris K Hansen, Carlyn Tan, Lauren C Peres, Rakesh Popat, Aimaz Afrough, Sireesha Asoori, Mrugakshi Dave, Andrew Portuguese, Efstathios Kastritis, James A Davis, Joaquin Martinez-Lopez, Douglas Sborov, Jana Mihalyova, Susan Bal, Murali Janakiram, Christopher Ferreri, Noa Biran, Megan Herr, Ariel Grajales-Cruz, Jack Khouri, Omar Castaneda Puglianini, Emily C Liang, Eli Zolotov, Gliceida Galarza Fortuna, Kelley Julian, Aishwarya Sannareddy, Larry D Anderson, Shahzad Raza, Danai Dima, Faiz Anwer, Shaji Kumar, Saad Usmani, Chiung-Yu Huang, Hira Mian, Surbhi Sidana, Krina Patel, Yi Lin, Luciano Costa
Zitieren
APA
Zanwar, S., Hansen, D. K., Pasvolsky, O., Tan, C., Peres, L. C., Goel, U., Popat, R., Afrough, A., Asoori, S., Rana, M., Dave, M., Portuguese, A., Kastritis, E., Davis, J. A., Martinez-Lopez, J., Sborov, D., Mihalyova, J., Bal, S., Janakiram, M., …, & US Multiple Myeloma Immunotherapy Consortium (2026). Early Treatment Failure in Patients With Relapsed/Refractory Multiple Myeloma Receiving Bispecific T-Cell Engagers: Development and Validation of the CHARGE Prognostic Index. Journal of Clinical Oncology. https://doi.org/10.1200/jco-26-01039
Vancouver
Zanwar S, Hansen DK, Pasvolsky O, Tan C, Peres LC, Goel U, et al. Early Treatment Failure in Patients With Relapsed/Refractory Multiple Myeloma Receiving Bispecific T-Cell Engagers: Development and Validation of the CHARGE Prognostic Index. Journal of Clinical Oncology. 2026. doi:10.1200/jco-26-01039
BibTeX
@article{Zanwar2026,
author = {Zanwar, Saurabh and Hansen, Doris K and Pasvolsky, Oren and Tan, Carlyn and Peres, Lauren C and Goel, Utkarsh and Popat, Rakesh and Afrough, Aimaz and Asoori, Sireesha and Rana, Masooma and Dave, Mrugakshi and Portuguese, Andrew and Kastritis, Efstathios and Davis, James A and Martinez-Lopez, Joaquin and Sborov, Douglas and Mihalyova, Jana and Bal, Susan and Janakiram, Murali and Pan, Darren and Shune, Leyla and Ferreri, Christopher and Biran, Noa and Herr, Megan and Grajales-Cruz, Ariel and Khouri, Jack and Corraes, Andre De Menezes Silva and Puglianini, Omar Castaneda and Liang, Emily C and Zolotov, Eli and Richards, Tiffany and Gaballa, Mahmoud and Fortuna, Gliceida Galarza and Julian, Kelley and Green, Kimberly and Sannareddy, Aishwarya and Anderson, Larry D and Raza, Shahzad and Dima, Danai and Mikkilineni, Lekha and Anwer, Faiz and Kumar, Shaji and Usmani, Saad and Huang, Chiung-Yu and Mian, Hira and Sidana, Surbhi and Patel, Krina and Martin, Thomas and Lin, Yi and Costa, Luciano and US Multiple Myeloma Immunotherapy Consortium, US Multiple Myeloma Immunotherapy Consortium},
title = {Early Treatment Failure in Patients With Relapsed/Refractory Multiple Myeloma Receiving Bispecific T-Cell Engagers: Development and Validation of the CHARGE Prognostic Index},
journal = {Journal of Clinical Oncology},
year = {2026},
doi = {10.1200/jco-26-01039}
}
EUVIMED